Troglitazone has several recognized therapeutic properties as a hypoglycemic agent, an antioxidant, a vasodilator agent, an anticonvulsant, an anticoagulant, a platelet aggregation inhibitor, an antineoplastic agent, an EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor and a ferroptosis inhibitor (National Center for Biotechnology Information, 2023h)
This amine functionalization enhanced hydrophilicity, surface charge balance, and nanochannel size, resulting in a fourfold increase in water permeance and over 96% selective dye removal through pH-responsive electrostatic interactions
If a serious reaction occurs, Emgality should be discontinued and appropriate therapy administered
& Hansen, J
The 503A/503B claims are some of the clearest among the five platforms, although the clinical oversight beyond that may be thin
aOoC models offer unique value for precision medicine, since they support the development of therapeutic strategies that are finely adapted to the biology of each individual patient
